Trump set to announce blockbuster deals with big pharma to slash drug prices

President Trump is set to unveil deals with multiple pharmaceutical companies in a Friday White House briefing as part of his 'Most Favored Nation' initiative to push U.S. drug prices down to the lowest prices in other developed countries; the briefing is expected to include representatives from at least five drugmakers. If these agreements are finalized, the measures could materially reduce pricing power and margins for affected drugmakers and prompt downward re-pricing in pharma equities, with the ultimate market impact hinging on which products are covered and the contractual terms of the deals.

Analysis

Market structure: MFN-style deals that force US prices toward lower international benchmarks will most directly compress branded pharma pricing power (large caps like PFE, MRK, LLY, BMY) and raise relative earnings for payors (UNH, CVS, CI). Expect headline-driven equity volatility over 1–5 trading days and fundamental EBITDA pressure for exposed drugs over 2–8 quarters — a 10–30% price cut on top-selling molecules would shave 3–8% off company-level revenue for affected names.

Risk assessment: Tail risks include aggressive rulemaking or importation (20%+ probability within 12 months) leading to deeper cuts or supply diversion; counter-party legal wins could reverse policy (30%+). Immediate risk (days) is headline volatility; medium (weeks–months) is contract implementation and Congressional/legal pushback; long-term (1–3 years) is R&D reallocation and launch delays that change growth trajectories.

Trade implications: Best relative-value outcome is long payors/insurers and short branded pharma; credit spreads for mid-grade pharma issuers could widen 10–40bps if consensus changes. Use size limits (2–4% NAV) and option overlays: buy 3–6 month put spreads on PFE/MRK to limit premium outlay while selling covered calls on UNH/CVS. React within 1–5 days to the White House announcement and reweight after 30–90 days as deal details emerge.

Contrarian angles: Consensus assumes uniform cuts; reality will be selective — companies with high oncology/biologic exposure (e.g., small-cap specialty biotech) may be spared or negotiate carve-outs. Overreaction risk: large-cap diversified pharma with strong non-US revenue might be oversold; if price cuts target older small-molecule drugs, pipeline valuations may hold. Historical parallel: 2016–2018 German reference pricing negotiations produced short-term stock hits but limited long-run earnings damage.

Key Decisions for Investors

• Establish a 2–3% NAV long in UNH and 1–2% in CVS (split total 3–5%) within 1–5 trading days to capture lower-cost-of-care tailwind; use small covered-call overlays (write 3-month calls 5–10% OTM) to finance carry.
• Initiate a 2% NAV short across PFE and MRK (1% each) using 3–6 month put spreads (e.g., buy 10% OTM puts, sell 20% OTM) to limit premium; increase to 4% NAV if announced deals imply >15% average price cuts for top 20 drugs.
• Run a pair trade: long UNH (2% NAV) / short PFE (2% NAV) equal-dollar for 3–12 months to capture insurer margin tailwinds versus branded pricing risk; rebalance if spread moves >8%.
• Buy 6–9 month protection (buy 1–2% NAV in put spreads) on mid-cap specialty pharma ETFs (e.g., XBI) if initial market reaction is >5% selloff — expected mean-reversion if cuts are selective; avoid broad biotech longs until 30–60 day regulatory clarity.
• Monitor deal details over next 30–60 days: if MFN deals explicitly include biologics or set a formulaic cap (e.g., <50% of current US price), raise short pharma exposure by +1–2% and trim insurer longs by 1%.